• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medication isn't effective. A customized treatment may be the answer.

Cue is a digital intervention platform that converts passively collected sensor data from smartphones into personalised micro-interventions designed to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to understand their predictors of feature and reveal distinct features that are able to change mood with time.

Predictors of Mood

Depression is one of the world's leading causes of mental illness.1 Yet, only half of people suffering from the condition receive treatment1. To improve the outcomes, doctors must be able identify and treat patients most likely to respond to certain treatments.

A customized depression treatment plan can aid. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit the most from specific treatments. They are using sensors for mobile phones as well as a voice assistant that incorporates artificial intelligence as well as other digital tools. With two grants awarded totaling more than $10 million, they will make use of these techniques to determine biological and behavioral predictors of the response to antidepressant medication and psychotherapy.

So far, the majority of research on factors that predict depression treatment effectiveness has focused on clinical and sociodemographic characteristics. These include demographic variables such as age, sex and education, clinical characteristics including the severity of symptoms and comorbidities and biological indicators such as neuroimaging and genetic variation.

A few studies have utilized longitudinal data in order to determine mood among individuals. They have not taken into account the fact that mood can vary significantly between individuals. Therefore, it is crucial to create methods that allow the recognition of the individual differences in mood predictors and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can systematically identify distinct patterns of behavior and emotions that vary between individuals.

The team also created a machine-learning algorithm that can identify dynamic predictors of the mood of each person's depression. The algorithm combines these personal characteristics into a distinctive "digital phenotype" for each participant.

This digital phenotype has been correlated with CAT DI scores that are a psychometrically validated symptoms severity scale. The correlation was not strong however (Pearson r = 0,08, BH adjusted P-value 3.55 x 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is a leading reason for disability across the world1, however, it is often not properly diagnosed and treated. Depressive disorders are often not treated because of the stigma associated with them, as well as the lack of effective interventions.

To aid in the development of a personalized treatment plan in order to provide a more personalized treatment, identifying factors that predict the severity of symptoms is crucial. The current methods for predicting symptoms rely heavily on clinical interviews, which are unreliable and only reveal a few symptoms associated with depression.

Machine learning is used to combine continuous digital behavioral phenotypes captured by sensors on smartphones and a validated online mental health tracker (the Computerized Adaptive Testing postpartum depression treatment Inventory CAT-DI) with other predictors of symptom severity can increase the accuracy of diagnostics and treatment efficacy for depression. These digital phenotypes are able to capture a variety of distinct behaviors and activities that are difficult to record through interviews and permit continuous, high-resolution measurements.

The study included University of California Los Angeles students with mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical treatment in accordance with their severity of depression. Participants who scored a high on the CAT-DI scale of 35 or 65 students were assigned online support by the help of a coach. Those with scores of 75 were routed to clinics in-person for psychotherapy.

At the beginning, participants answered the answers to a series of questions concerning their personal characteristics and psychosocial traits. The questions asked included age, sex and education and financial status, marital status, whether they were divorced or not, the frequency of suicidal thoughts, intentions or attempts, as well as how often they drank. Participants also rated their level of depression symptom severity on a scale of 0-100 using the CAT-DI. CAT-DI assessments were conducted every week for those that received online support, and once a week for those receiving in-person care.

Predictors of Treatment Response

Personalized depression treatment is currently a major research area and a lot of studies are aimed at identifying predictors that will allow clinicians to identify the most effective medication for each individual. Pharmacogenetics in particular uncovers genetic variations that affect how the human body metabolizes drugs. This lets doctors select the medication that will likely work best for each patient, reducing the amount of time and effort required for trial-and error treatments and avoid any negative side effects.

Another promising approach is to build predictive models that incorporate information from clinical studies and neural imaging data. These models can be used to determine the variables that are most predictive of a particular outcome, such as whether a medication can improve symptoms or mood. These models can be used to predict the response of a patient to a treatment, which will help doctors to maximize the effectiveness.

A new era of research employs machine learning techniques, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and increase predictive accuracy. These models have been demonstrated to be effective in predicting the outcome of treatment, such as response to antidepressants. These techniques are becoming increasingly popular in psychiatry, and are likely to become the norm in the future treatment.

The study of depression's underlying mechanisms continues, as well as ML-based predictive models. Recent research suggests that depression treatment without antidepressants is related to the dysfunctions of specific neural networks. This theory suggests that individualized depression ect treatment for depression will be built around targeted treatments that target these circuits to restore normal function.

Internet-delivered interventions can be an effective method to accomplish this. They can provide a more tailored and individualized experience for patients. For example, one study found that a program on the internet was more effective than standard treatment in alleviating symptoms and ensuring an improved quality of life for people with MDD. In addition, a controlled randomized trial of a personalized treatment for depression demonstrated an improvement in symptoms and fewer adverse effects in a large percentage of participants.

Predictors of side effects

A major challenge in personalized depression non drug treatment for depression involves identifying and predicting which antidepressant medications will have very little or no side effects. Many patients experience a trial-and-error approach, with several medications prescribed before finding one that is safe and effective. Pharmacogenetics offers a fresh and exciting way to select antidepressant medicines that are more effective and precise.

Many predictors can be used to determine which antidepressant to prescribe, including genetic variants, patient phenotypes (e.g., sex or ethnicity) and co-morbidities. However, identifying the most reliable and valid predictive factors for a specific treatment will probably require randomized controlled trials with much larger samples than those typically enrolled in clinical trials. This is due to the fact that the identification of moderators or interaction effects can be a lot more difficult in trials that only consider a single episode of treatment per person instead of multiple episodes of treatment over a period of time.

In addition, predicting a patient's response will likely require information on comorbidities, symptom profiles and the patient's own experience of tolerability and effectiveness. There are currently only a few easily assessable sociodemographic variables and clinical variables appear to be reliable in predicting the response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.

The application of pharmacogenetics in depression treatment is still in its beginning stages and there are many hurdles to overcome. first line treatment for depression and anxiety, it is essential to be able to comprehend and understand the definition of the genetic mechanisms that underlie depression, and a clear definition of a reliable predictor of treatment response. Ethics, such as privacy, and the ethical use of genetic information are also important to consider. Pharmacogenetics can, in the long run, reduce stigma surrounding mental health treatments and improve the quality of treatment. Like any other psychiatric electromagnetic treatment for depression, it is important to take your time and carefully implement the plan. The best course of action is to provide patients with a variety of effective depression medication options and encourage them to talk freely with their doctors about their concerns and experiences.